In this Issue:
Nivolumab superior to docetaxel in squamous cell NSCLC
Nivolumab superior to docetaxel in non-squamous cell NSCLC
Adjunctive bevacizumab prolongs survival in mesothelioma
Efficacy signal for pembrolizumab in SCLC
Efficacy signal for nivolumab plus ipilimumab vs nivolumab in SCLC?
AZD9291: effective in EGFR mutation-positive NSCLC?
Circulating tumour DNA predicts response to rocelitinib in NSCLC
Afatinib better than erlotinib inlung squamous cell carcinoma
Please login below to download this issue (PDF)